Rain Oncology Plummets after Lead Candidate Disappoints in Phase 3

Shares of precision oncology company Rain Oncology (NASDAQ:RAIN) fell off a cliff Monday after its lead product candidate failed to meet the primary endpoint in a Phase 3 trial for the treatment of dedifferentiated liposarcoma (DD LPS).